Company / Operating Cash Flow per Share
Sarepta Therapeutics Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$2.12
FY2025
5-year range
-$5.70 / $1.23
FY2021-FY2025
Trend
+3.4%
vs FY2024
Sector context
#150 of 212
Health Care
What the data says
At $-2.12, Sarepta Therapeutics's operating cash flow per share ranks #150 of 212 in the Health Care sector. Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-6.00 in FY2018 to $1.23 in FY2022.
Based on SEC 10-K filings.
-2.12 in FY2025.
Improved from $-5.70 to $-2.12 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#150 of 212 in Health CareTop 71% of 212This company -$2.12 Sector average -$14.72
▼
+85.6% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 3.4% year-over-year.
- Ranks #150 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2022.
- Lowest operating cash flow per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.12 | +3.4% |
| FY2024 | -$2.20 | +61.5% |
| FY2023 | -$5.70 | -561.8% |
| FY2022 | $1.23 | +122.1% |
| FY2021 | -$5.58 | -8.0% |
| FY2020 | -$5.17 | -58.4% |
| FY2019 | -$3.26 | +45.6% |
| FY2018 | -$6.00 | -41.6% |
| FY2017 | -$4.24 | +21.4% |
| FY2016 | -$5.39 | -52.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026